Research

Hormonal

Semaglutide use is associated with a high incidence of gastrointestinal adverse events, including nausea, vomiting, diarrhea, and constipation, with signal strength varying by clinical priority and time-to-onset.

If you are taking semaglutide, expect gastrointestinal side effects like nausea, vomiting, or diarrhea, especially when starting or increasing the dose. These are common and often decrease over time. Discuss starting with a lower dose and titrating slowly with your provider to improve tolerance. Ensure you stay hydrated and eat smaller, bland meals if symptoms occur.

ModerateSupportsMEDIUM confidence
We identified 5,442 cases of semaglutide-associated gastrointestinal AEs, with 45 signals detected... The most frequently reported gastrointestinal AEs were nausea (n = 2,369), vomiting (n = 1,338), diarrhea (n = 1,195), constipation (n = 663)...
Yamin Shu et al. · Frontiers in Public Health · 2022

Why this rating

Real-world pharmacovigilance data (FAERS) provides large sample size but lacks controlled randomization and precise dosing protocols for individual patients.

Source

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system

Yamin Shu et al. · Frontiers in Public Health · 2022

DOI 10.3389/fpubh.2022.996179

cohort · n=5442Cited 118×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →